Literature DB >> 9306023

Modulation by mexiletine of action potentials, L-type Ca current and delayed rectifier K current recorded from isolated rabbit atrioventricular nodal myocytes.

J S Mitcheson1, J C Hancox.   

Abstract

Using whole-cell patch clamp recordings at 37 degrees C, we have examined the effects of externally applied mexiletine (a class 1b antiarrhythmic agent) on action potentials, L-type Ca current (ICa, L) and delayed rectifier K current (IK) in single isolated rabbit atrioventricular nodal (AVN) myocytes. In spontaneously active AVN cells, 30-100 micro;M mexiletine depolarised the maximum diastolic potential and slowed both action potential upstroke and repolarisation. Under selective recording conditions for ICa,L, mexiletine reduced peak ICa,L (at +10 mV) amplitude in a dose-dependent fashion (41.8 +/- 3.0% inhibition by 100 micro;M and 16.4 +/- 1.8% at 30 micro;M). The voltage dependence of ICa,L activation was unaffected by both concentrations of the drug. Under selective recording conditions, IK amplitude was measured as the peak of the deactivating tail current following a depolarising voltage pulse to +20 mV. 30 micro;M mexiletine inhibited IK by 34.3 +/- 5.8%, whilst 100 micro;M mexiletine reduced the current by 52.7 +/- 6.1%. The effects of mexiletine on ICa,L and IK are likely to contribute significantly to the changes in action potentials observed in spontaneously active cells. These findings are also suggestive of key roles for ICa,L and IK in determining the shape and rate of action potentials in this region of the heart.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306023     DOI: 10.1007/s004240050476

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  8 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

3.  Modulation by endothelin-1 of spontaneous activity and membrane currents of atrioventricular node myocytes from the rabbit heart.

Authors:  Stéphanie C Choisy; Hongwei Cheng; Godfrey L Smith; Andrew F James; Jules C Hancox
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

4.  Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.

Authors:  Roberta Gualdani; Francesco Tadini-Buoninsegni; Mariagrazia Roselli; Ivana Defrenza; Marialessandra Contino; Nicola Antonio Colabufo; Giovanni Lentini
Journal:  Pharmacol Res Perspect       Date:  2015-07-31

Review 5.  Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy.

Authors:  Gavin Y Oudit; Maria G Trivieri; Neelam Khaper; Peter P Liu; Peter H Backx
Journal:  J Mol Med (Berl)       Date:  2006-04-08       Impact factor: 4.599

6.  Purkinje Cells as Sources of Arrhythmias in Long QT Syndrome Type 3.

Authors:  Vivek Iyer; Danilo Roman-Campos; Kevin J Sampson; Guoxin Kang; Glenn I Fishman; Robert S Kass
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

7.  Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.

Authors:  Chunyun Du; Yihong Zhang; Aziza El Harchi; Christopher E Dempsey; Jules C Hancox
Journal:  J Mol Cell Cardiol       Date:  2014-05-27       Impact factor: 5.000

8.  An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes.

Authors:  Wesley L McKeithan; Alex Savchenko; Michael S Yu; Fabio Cerignoli; Arne A N Bruyneel; Jeffery H Price; Alexandre R Colas; Evan W Miller; John R Cashman; Mark Mercola
Journal:  Front Physiol       Date:  2017-10-11       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.